


525 Rec'd

22 JUL 2002



Docket No.: 220243US0PCT

OBLON

SPIVAK

McCLELLAND

MAIER

&  
NEUSTADT

P.C.

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

RE: Application Serial No.: 10/070,474  
Applicants: Stephen ARKINSTALL, et al.  
Filing Date: March 20, 2002  
For: PHARMACEUTICALLY ACTIVE SULFONYL  
HYDRAZIDE DERIVATIVES

ATTORNEYS AT LAW

RECEIVED  
AUG 06 2002  
TECH CENTER 1600/126000

SIR:

Attached hereto for filing are the following papers:

**Response and Statement (2 pp.)**  
**Filing of Declaration under 37 CFR 1.53(f)**  
**Declaration, Power of Attorney and Petition (6 pages)(executed)**  
**Return Copy - Notification of Missing Requirements**

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon  
Attorney of Record  
Registration No. 24,618



22850

James J. Kelly, Ph.D.  
Registration No. 41,504

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

Docket No.

220243US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Stephen ARKINSTAEL, et al.

SERIAL NUMBER: 10/070,474

ATTN: APPLICATION BRANCH

FILING DATE: March 20, 2002

FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

**FILING OF DECLARATION UNDER 37 CFR 1.53(f)**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:


Responsive to the notification dated May 20, 2002, and in accordance with the provisions of 37 CFR 1.53(f), Applicants submit herewith a Rule 63 Declaration. The required fee was paid at the time of filing the application.

The Declaration enclosed herewith contains the Title of the Invention and Inventor(s) name(s) and is believed, in combination with the application serial number and filing date contained in this cover letter, to adequately identify the above-identified application in accordance with 37 CFR 1.63, as set forth in MPEP Section 601.01.

In light of the foregoing, this application is deemed to be in proper condition for examination and such favorable action is earnestly solicited.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
\_\_\_\_\_  
Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

James J. Kelly, Ph.D.  
Registration No. 24,618



**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/98)

220243US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
Stephen ARKINSTALL, et al. :  
SERIAL NO: 10/070,474 :  
FILED: March 20, 2002 :  
FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

RESPONSE TO NOTICE

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Notice dated May 20, 2002, Applicants submit herewith a  
Declaration in compliance with 37 C.F.R. §1.497 and the following Response To Notice.

REMARKS

Claims 1-27 are active in the present application. Favorable consideration is  
respectfully requested.

Applicants respectfully submit that no Sequence Listing is required to be filed in the  
present Application. No Sequence Listing was originally filed in the present application, nor  
is one required in the present application. The Office has mistakenly indicated that  
Applicants have originally filed a "Biochemical Sequence Listing" in the present application.  
Therefore, the Office has erroneously required a computer readable form Sequence Listing  
and Statement under 37 C.F.R. §1.821-1.825. Accordingly, Applicants respectfully request


that the requirement to file a computer readable form Sequence Listing and a Statement in the Notice of May 20, 2002, be withdrawn.

In addition, Applicants timely file herewith the Declaration in compliance with 37 C.F.R. §1.497.

Applicants submit that this application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

James J. Kelly, Ph.D.  
Registration No.: 41,504



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
NFO/JK/TWB:sjh  
I:\atty\Twb\220243-pr.wpd